Clavis Pharma ASA : Clavis Pharma ASA : Invitation to presentation and webcast of Clavis Pharma's fourth quarter results 2012

Clavis Pharma ASA : Clavis Pharma ASA : Invitation to presentation and webcast
                of Clavis Pharma's fourth quarter results 2012

Invitation to presentation and webcast of Clavis Pharma's fourth quarter
results 2012

Oslo, Norway, 7 February 2013

Clavis Pharma ASA (OSE: CLAVIS) presents the company's fourth quarter 2012
results on Friday 15 February 2013 at Hotel Continental, Stortingsgaten 24/26,
Oslo, Norway.

The presentation will start at 08:30(CET).

Following the presentation, there will be a Q&A session. Breakfast will be
served from 08.00 (CET).

The presentation will also be webcast live and can be accessed directly from
WEBCAST or clavispharma.com. Questions can be submitted live during the
presentation.

The quarterly report and presentation will be available at
clavispharma.com/investors.

Clavis Pharma welcomes all interested parties.

Contacts:
Olav Hellebø
Chief Executive Officer
+47 24 11 09 50
olav.hellebo@clavispharma.com

Gunnar Manum
Chief Financial Officer
+47 24 11 09 71
+47 95 17 91 90 (mob)
gunnar.manum@clavispharma.com

Mark Swallow / Nina Enegren / David Dible
Citigate Dewe Rogerson
+44 207 282 2948
clavispharma@citigatedr.co.uk

Peter Rahmer (US Investor enquiries)
The Trout Group
+1 646 378 2973 Direct / + 646 272 8526 Cell
prahmer@troutgroup.com

About Clavis Pharma

Clavis Pharma ASA is a clinical-stage pharmaceutical company developing novel
anti-cancer drugs and companion diagnostics to identify patient populations
that may benefit from treatment with these agents. Clavis' development
pipeline includes novel patented versions of well-established and commercially
successful drugs, made using the Company's proprietary Lipid Vector Technology
(LVT), which may offer a better efficacy /safety profile compared to the
parent compounds. 

The Company's lead product, Elacytarabine, is in a randomized, controlled
Phase III study (the CLAVELA study) that recently completed recruitment in
relapsed or refractory acute myeloid leukaemia. The Company is also
investigating CP-4200, an azacitidine derivative, in preclinical studies for
myelodysplastic syndrome, a disease that is often a precursor to leukaemia. 

Clavis Pharma intends to commercialise its products through strategic
alliances and partnerships with experienced oncology businesses and, where and
when commercially appropriate, by establishing its own sales and marketing
capabilities. 

Clavis Pharma is based in Oslo, Norway and listed on the Oslo Stock Exchange
(ticker: CLAVIS).

www.clavispharma.com

Forward-looking statements

This release and any materials distributed in connection with this release may
contain certain forward-looking statements. By their nature, forward-looking
statements involve risk and uncertainty because they reflect the Company's
current expectations and assumptions as to future events and circumstances
that may not prove accurate. A number of material factors could cause actual
results and developments to differ materially from those expressed or implied
by these forward-looking statements.

This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Clavis Pharma ASA via Thomson Reuters ONE
HUG#1676288